S&P 500   3,006.41 (-0.01%)
DOW   26,887.10 (+0.22%)
QQQ   192.64 (-0.39%)
AAPL   241.80 (+0.54%)
FB   183.90 (-3.09%)
MSFT   137.41 (-0.74%)
GOOGL   1,244.90 (+0.05%)
AMZN   1,771.01 (-0.82%)
NVDA   197.22 (+0.62%)
GE   8.99 (+2.28%)
TSLA   256.76 (+1.29%)
AMD   31.76 (-0.87%)
T   38.21 (-0.05%)
F   9.08 (+0.44%)
ACB   3.62 (-1.90%)
PRI   125.86 (+0.14%)
NFLX   269.06 (-3.24%)
BAC   31.28 (+0.81%)
GILD   66.32 (+1.70%)
DIS   133.29 (+2.33%)
S&P 500   3,006.41 (-0.01%)
DOW   26,887.10 (+0.22%)
QQQ   192.64 (-0.39%)
AAPL   241.80 (+0.54%)
FB   183.90 (-3.09%)
MSFT   137.41 (-0.74%)
GOOGL   1,244.90 (+0.05%)
AMZN   1,771.01 (-0.82%)
NVDA   197.22 (+0.62%)
GE   8.99 (+2.28%)
TSLA   256.76 (+1.29%)
AMD   31.76 (-0.87%)
T   38.21 (-0.05%)
F   9.08 (+0.44%)
ACB   3.62 (-1.90%)
PRI   125.86 (+0.14%)
NFLX   269.06 (-3.24%)
BAC   31.28 (+0.81%)
GILD   66.32 (+1.70%)
DIS   133.29 (+2.33%)
Log in

Acceleron Pharma News Headlines (NASDAQ:XLRN)

$43.11
+0.58 (+1.36 %)
(As of 10/22/2019 02:32 PM ET)
Today's Range
$42.74
Now: $43.11
$43.46
50-Day Range
$38.40
MA: $42.21
$46.38
52-Week Range
$37.01
Now: $43.11
$59.08
Volume6,723 shs
Average Volume288,020 shs
Market Capitalization$2.27 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.25

Headlines

Acceleron Pharma (NASDAQ XLRN) News Headlines

Source:
DateHeadline
Acceleron Pharmas (XLRN) "Buy" Rating Reiterated at CowenAcceleron Pharma's (XLRN) "Buy" Rating Reiterated at Cowen
www.americanbankingnews.com - October 13 at 9:16 PM
Morgan Stanley Lowers Acceleron Pharma (NASDAQ:XLRN) Price Target to $48.00Morgan Stanley Lowers Acceleron Pharma (NASDAQ:XLRN) Price Target to $48.00
www.americanbankingnews.com - October 11 at 2:01 PM
One Thing To Remember About The Acceleron Pharma Inc. (NASDAQ:XLRN) Share PriceOne Thing To Remember About The Acceleron Pharma Inc. (NASDAQ:XLRN) Share Price
finance.yahoo.com - October 10 at 6:29 PM
Acceleron Pharma Inc (NASDAQ:XLRN) Receives Consensus Rating of "Buy" from BrokeragesAcceleron Pharma Inc (NASDAQ:XLRN) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - October 8 at 6:54 AM
Acceleron Pharma Inc (NASDAQ:XLRN) Expected to Post Quarterly Sales of $3.45 MillionAcceleron Pharma Inc (NASDAQ:XLRN) Expected to Post Quarterly Sales of $3.45 Million
www.americanbankingnews.com - October 6 at 2:19 PM
Here’s Why Acceleron Pharma Stock Fell 12% in SeptemberHere’s Why Acceleron Pharma Stock Fell 12% in September
www.fool.com - October 5 at 4:48 PM
 Analysts Expect Acceleron Pharma Inc (NASDAQ:XLRN) to Post -$0.81 Earnings Per Share Analysts Expect Acceleron Pharma Inc (NASDAQ:XLRN) to Post -$0.81 Earnings Per Share
www.americanbankingnews.com - October 4 at 7:47 AM
Critical Analysis: Acceleron Pharma (NASDAQ:XLRN) vs. Mymetics (NASDAQ:MYMX)Critical Analysis: Acceleron Pharma (NASDAQ:XLRN) vs. Mymetics (NASDAQ:MYMX)
www.americanbankingnews.com - September 29 at 12:15 AM
Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & MoreBiotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More
www.msn.com - September 20 at 12:17 AM
Acceleron Gives Up on Rare Genetic Disease. Analysts Are Still Bullish on the Stock.Acceleron Gives Up on Rare Genetic Disease. Analysts Are Still Bullish on the Stock.
finance.yahoo.com - September 17 at 12:19 PM
This Biotech Just Flopped On A Test; Why Analysts Remain BullishThis Biotech Just Flopped On A Test; Why Analysts Remain Bullish
finance.yahoo.com - September 17 at 12:19 PM
Biogen, Acceleron terminate drugs after poor trialsBiogen, Acceleron terminate drugs after poor trials
www.bizjournals.com - September 17 at 8:15 AM
Acceleron bails on candidate ACE-083; shares down 3% after hoursAcceleron bails on candidate ACE-083; shares down 3% after hours
seekingalpha.com - September 16 at 6:01 PM
Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Facioscapulohumeral Muscular DystrophyAcceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Facioscapulohumeral Muscular Dystrophy
finance.yahoo.com - September 16 at 6:00 PM
Acceleron Pharma stock down 4% after company halts treatment trialAcceleron Pharma stock down 4% after company halts treatment trial
finance.yahoo.com - September 16 at 6:00 PM
FDA Grants Orphan Drug Status to Accelerons PAH CandidateFDA Grants Orphan Drug Status to Acceleron's PAH Candidate
finance.yahoo.com - September 11 at 6:56 AM
Accelerons Pulmonary Arterial Hypertension Asset Receives Orphan Drug DesignationAcceleron's Pulmonary Arterial Hypertension Asset Receives Orphan Drug Designation
www.benzinga.com - September 9 at 11:46 AM
Acceleron Receives FDA Orphan Drug Designation for Sotatercept in Pulmonary Arterial HypertensionAcceleron Receives FDA Orphan Drug Designation for Sotatercept in Pulmonary Arterial Hypertension
finance.yahoo.com - September 9 at 11:46 AM
Acceleron Pharma Breaks Below 200-Day Moving Average - Notable for XLRNAcceleron Pharma Breaks Below 200-Day Moving Average - Notable for XLRN
www.nasdaq.com - September 5 at 3:38 PM
Should You Worry About Acceleron Pharma Inc.s (NASDAQ:XLRN) CEO Pay Cheque?Should You Worry About Acceleron Pharma Inc.'s (NASDAQ:XLRN) CEO Pay Cheque?
finance.yahoo.com - August 20 at 11:07 AM
Should You Worry About Acceleron Pharma Inc.'s (NASDAQ:XLRN) CEO Pay Cheque?Should You Worry About Acceleron Pharma Inc.'s (NASDAQ:XLRN) CEO Pay Cheque?
finance.yahoo.com - August 20 at 11:07 AM
Edited Transcript of XLRN earnings conference call or presentation 5-Aug-19 9:00pm GMTEdited Transcript of XLRN earnings conference call or presentation 5-Aug-19 9:00pm GMT
finance.yahoo.com - August 6 at 11:52 PM
Acceleron Pharma Inc (XLRN) Q2 2019 Earnings Call TranscriptAcceleron Pharma Inc (XLRN) Q2 2019 Earnings Call Transcript
www.fool.com - August 6 at 11:28 AM
What You'll Want to Know About Acceleron Pharma's Q2 UpdateWhat You'll Want to Know About Acceleron Pharma's Q2 Update
finance.yahoo.com - August 6 at 9:06 AM
What Youll Want to Know About Acceleron Pharmas Q2 UpdateWhat You'll Want to Know About Acceleron Pharma's Q2 Update
www.fool.com - August 6 at 7:46 AM
ALNY To Face FDA In Feb., PODD Ups Outlook Again, Catalysts Galore For XLRN ALNY To Face FDA In Feb., PODD Ups Outlook Again, Catalysts Galore For XLRN
www.rttnews.com - August 6 at 4:38 AM
Acceleron Pharma EPS misses by $0.11, misses on revenueAcceleron Pharma EPS misses by $0.11, misses on revenue
seekingalpha.com - August 5 at 11:41 PM
Acceleron Pharma Q2 2019 Earnings PreviewAcceleron Pharma Q2 2019 Earnings Preview
seekingalpha.com - August 4 at 10:37 PM
Are Insiders Selling Acceleron Pharma Inc. (NASDAQ:XLRN) Stock?Are Insiders Selling Acceleron Pharma Inc. (NASDAQ:XLRN) Stock?
finance.yahoo.com - July 15 at 6:59 PM
Acceleron Pharma Inc. Common Stock Historical Stock PricesAcceleron Pharma Inc. Common Stock Historical Stock Prices
www.nasdaq.com - July 8 at 6:48 PM
Acceleron Pharma Inc. Institutional OwnershipAcceleron Pharma Inc. Institutional Ownership
www.nasdaq.com - July 8 at 6:48 PM
Acceleron completes enrollment in mid-stage study of sotatercept in PAHAcceleron completes enrollment in mid-stage study of sotatercept in PAH
seekingalpha.com - June 26 at 8:26 AM
Acceleron Pharma Inc. (NASDAQ:XLRN): Financial Strength AnalysisAcceleron Pharma Inc. (NASDAQ:XLRN): Financial Strength Analysis
finance.yahoo.com - June 15 at 12:26 AM
Acceleron co-founder bids adieuAcceleron co-founder bids adieu
seekingalpha.com - June 10 at 8:32 AM
Acceleron Announces Retirement of Director and Co-Founder Tom ManiatisAcceleron Announces Retirement of Director and Co-Founder Tom Maniatis
finance.yahoo.com - June 10 at 8:32 AM
Celgene & Accelerons BLA for Luspatercept Accepted by FDACelgene & Acceleron's BLA for Luspatercept Accepted by FDA
finance.yahoo.com - June 6 at 7:07 PM
Celgene & Acceleron's BLA for Luspatercept Accepted by FDACelgene & Acceleron's BLA for Luspatercept Accepted by FDA
finance.yahoo.com - June 6 at 7:07 PM
BIO 2019: Gene therapy surging, but challenges remainBIO 2019: Gene therapy surging, but challenges remain
www.bizjournals.com - June 5 at 6:58 PM
Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-ThalassemiaCelgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia
finance.yahoo.com - June 4 at 8:24 AM
The Investment Thesis On Acceleron PharmaThe Investment Thesis On Acceleron Pharma
seekingalpha.com - May 28 at 8:19 AM
Acceleron to Present at the UBS Global Healthcare ConferenceAcceleron to Present at the UBS Global Healthcare Conference
finance.yahoo.com - May 14 at 8:40 AM
Edited Transcript of XLRN earnings conference call or presentation 9-May-19 9:00pm GMTEdited Transcript of XLRN earnings conference call or presentation 9-May-19 9:00pm GMT
finance.yahoo.com - May 10 at 6:55 PM
Acceleron Pharmas (XLRN) CEO Habib Dable on Q1 2019 Results - Earnings Call TranscriptAcceleron Pharma's (XLRN) CEO Habib Dable on Q1 2019 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 8:23 AM
Acceleron Pharma (XLRN) Reports Q1 Loss, Misses Revenue EstimatesAcceleron Pharma (XLRN) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 10 at 8:23 AM
Acceleron Pharma Inc (XLRN) Q1 2019 Earnings Call TranscriptAcceleron Pharma Inc (XLRN) Q1 2019 Earnings Call Transcript
www.fool.com - May 9 at 11:13 PM
Acceleron Reports First Quarter 2019 Operating and Financial ResultsAcceleron Reports First Quarter 2019 Operating and Financial Results
www.businesswire.com - May 9 at 7:45 PM
Acceleron Pharma misses by $0.10, misses on revenueAcceleron Pharma misses by $0.10, misses on revenue
seekingalpha.com - May 9 at 7:45 PM
Acceleron Pharma Q1 2019 Earnings PreviewAcceleron Pharma Q1 2019 Earnings Preview
seekingalpha.com - May 8 at 7:38 PM
Can Epidolex Drive GW Pharmaceuticals' (GWPH) Q2 Earnings?Can Epidolex Drive GW Pharmaceuticals' (GWPH) Q2 Earnings?
finance.yahoo.com - May 6 at 8:21 AM
Acceleron to Webcast First Quarter 2019 Operating and Financial Results on May 9, 2019Acceleron to Webcast First Quarter 2019 Operating and Financial Results on May 9, 2019
finance.yahoo.com - May 1 at 8:17 AM
This page was last updated on 10/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel